Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Viatris Inc (VTRS) Price & Performance

iShares 1 3 Year Treasury Bond ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares 1 3 Year Treasury Bond ETF vs Viatris Inc — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.2 (market cap $26.68B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: iShares 1 3 Year Treasury Bond ETF is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 63 Days and Viatris Inc for 57 Days on average.

SHYVTRS
Market Cap
$26.68B$20.03B
Volume
4,077,69114,109,977
Sector
Fixed IncomeHealth
52-Week High
$83.18$18.27
52-Week Low
$81.05$9.74
Typical Hold Time
63 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 1 3 Year Treasury Bond ETF

SHY trades at $81.20 with minimal daily movement (+0.05%), reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend payments of $0.24-$0.25 per share provide income stability, though key financial ratios are unavailable for fundamental assessment. The bond ETF faces headwinds from rising Treasury yields and inflation concerns.

Outlook remains cautious as rising interest rates pressure bond ETFs, though SHY's short-term focus may offer relative safety. Key risks include prolonged high yields and economic uncertainty. Investment appeal hinges on income generation in a volatile rate environment, with technical weakness suggesting limited near-term upside.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SHY
100% Buy0% Sell
Avg holding period · 63 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →